Liraglutide in the treatment of Type 2 diabetes: Clinical data and practical considerations for its use

Francisco Javier Ampudia-Blasco; Carlos Calvo Gmez; Xavier Cos Claramunt; Javier Garca Alegra; Esteban Jdar Gimeno; José Javier Mediavilla Bravo; Pedro Mezquita Raya; Jorge Navarro Pérez; Manel Puig Domingo

doi:10.1586/eem.10.59

Liraglutide in the treatment of Type 2 diabetes: Clinical data and practical considerations for its use

Francisco Javier Ampudia-Blasco, Carlos Calvo Gmez, Xavier Cos Claramunt, Javier Garca Alegra, Esteban Jdar Gimeno, José Javier Mediavilla Bravo, Pedro Mezquita Raya, Jorge Navarro Pérez, Manel Puig Domingo

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

1 Citation (Scopus)

Abstract

Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA1c) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM. © 2010 Expert Reviews Ltd.

Original language	English
Pages (from-to)	799-807
Journal	Expert Review of Endocrinology and Metabolism
Volume	5
Issue number	6
DOIs	https://doi.org/10.1586/eem.10.59
Publication status	Published - 1 Nov 2010

Keywords

GLP-1 analog
glycemic control
incretin
liraglutide
Type 2 diabetes mellitus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/eem.10.59

Cite this

@article{fb1c6b2868b04c7895fa408881510600,

title = "Liraglutide in the treatment of Type 2 diabetes: Clinical data and practical considerations for its use",

abstract = "Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA1c) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM. {\textcopyright} 2010 Expert Reviews Ltd.",

keywords = "GLP-1 analog, glycemic control, incretin, liraglutide, Type 2 diabetes mellitus",

author = "Ampudia-Blasco, {Francisco Javier} and Gmez, {Carlos Calvo} and Claramunt, {Xavier Cos} and Alegra, {Javier Garca} and Gimeno, {Esteban Jdar} and Bravo, {Jos{\'e} Javier Mediavilla} and Raya, {Pedro Mezquita} and P{\'e}rez, {Jorge Navarro} and Domingo, {Manel Puig}",

year = "2010",

month = nov,

day = "1",

doi = "10.1586/eem.10.59",

language = "English",

volume = "5",

pages = "799--807",

journal = "Expert Review of Endocrinology and Metabolism",

issn = "1744-6651",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Liraglutide in the treatment of Type 2 diabetes: Clinical data and practical considerations for its use

AU - Ampudia-Blasco, Francisco Javier

AU - Gmez, Carlos Calvo

AU - Claramunt, Xavier Cos

AU - Alegra, Javier Garca

AU - Gimeno, Esteban Jdar

AU - Bravo, José Javier Mediavilla

AU - Raya, Pedro Mezquita

AU - Pérez, Jorge Navarro

AU - Domingo, Manel Puig

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA1c) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM. © 2010 Expert Reviews Ltd.

AB - Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA1c) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM. © 2010 Expert Reviews Ltd.

KW - GLP-1 analog

KW - glycemic control

KW - incretin

KW - liraglutide

KW - Type 2 diabetes mellitus

U2 - 10.1586/eem.10.59

DO - 10.1586/eem.10.59

M3 - Review article

SN - 1744-6651

VL - 5

SP - 799

EP - 807

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

IS - 6

ER -

Liraglutide in the treatment of Type 2 diabetes: Clinical data and practical considerations for its use

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this